益生菌治疗炎性肠病的研究进展  

Research progress of probiotics in the treatment of inflammatory bowel disease

作　　者：杨敏琪(综述) 张吉翔(综述)[1] 董卫国(审校)[1] Yang Minqi;Zhang Jixiang;Dong Weiguo(Department of Gastroenterology,Renmin Hospital,Wuhan University,Hubei Province,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院消化内科,430060

出　　处：《疑难病杂志》2022年第11期1202-1205,共4页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金资助项目(81870392)。

摘　　要：炎性肠病(IBD)是一种涉及环境、饮食、遗传、肠道菌群等多种因素的慢性肠道炎性疾病。我国IBD发病率逐渐升高,但氨基水杨酸制剂、糖皮质激素、免疫抑制剂、生物制剂等现有治疗方法存在价格高、安全性低、不良反应明显、治疗作用有限等缺点。现已发现益生菌在调节肠道菌群、减轻肠道炎性反应、调节肠道免疫等方面功效显著,现就肠道菌群与IBD的关系、益生菌在IBD治疗中的临床应用及其作用机制予以综述。Inflammatory bowel disease(IBD)is a chronic intestinal inflammatory disease involving environment,diet,genetics,intestinal flora and other factors.The incidence of IBD is gradually increasing in China,but the existing treatment methods such as aminosalicylic acid,glucocorticoid,immunosuppressant and biological agents have shortcomings such as high price,low safety,obvious adverse reactions and limited therapeutic effect.It has been found that probiotics have significant effects in regulating intestinal flora,reducing intestinal inflammatory response,regulating intestinal immunity,etc.This article reviews the relationship between intestinal flora and IBD,the clinical application of probiotics in the treatment of IBD and its mechanism.

关 键 词：炎性肠病 肠道菌群 益生菌 治疗 

分 类 号：R574[医药卫生—消化系统]